BR9913746E8 - derivado de piridínio, processo para a preparação do composto, uso do composto, composição farmacêutica para o tratamento de complicações diabéticas e doenças relacionadas ao envelhecimento, processo para preparação de uma formulação parenteral,processo para o tratamento de um paciente diabético pela ruptura de um age pré-formado dentro do paciente,e,processo de prevenção ou de tratamento de doenças causadas por diabetes e por complicações relacionadas com o envelhecimento. - Google Patents

derivado de piridínio, processo para a preparação do composto, uso do composto, composição farmacêutica para o tratamento de complicações diabéticas e doenças relacionadas ao envelhecimento, processo para preparação de uma formulação parenteral,processo para o tratamento de um paciente diabético pela ruptura de um age pré-formado dentro do paciente,e,processo de prevenção ou de tratamento de doenças causadas por diabetes e por complicações relacionadas com o envelhecimento.

Info

Publication number
BR9913746E8
BR9913746E8 BRC19913746A BR9913746A BR9913746E8 BR 9913746 E8 BR9913746 E8 BR 9913746E8 BR C19913746 A BRC19913746 A BR C19913746A BR 9913746 A BR9913746 A BR 9913746A BR 9913746 E8 BR9913746 E8 BR 9913746E8
Authority
BR
Brazil
Prior art keywords
treating
aging
patient
complications
diabetic
Prior art date
Application number
BRC19913746A
Other languages
English (en)
Other versions
BRPI9913746B8 (pt
BRPI9913746F8 (pt
BR9913746F8 (pt
BR9913746F1 (pt
BR9913746B1 (pt
BR9913746A (pt
BR9913746C1 (pt
Inventor
Sankaranarayanan Alangudi
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of BR9913746A publication Critical patent/BR9913746A/pt
Publication of BR9913746C1 publication Critical patent/BR9913746C1/pt
Publication of BR9913746B1 publication Critical patent/BR9913746B1/pt
Publication of BR9913746E8 publication Critical patent/BR9913746E8/pt
Publication of BR9913746F1 publication Critical patent/BR9913746F1/pt
Publication of BRPI9913746B8 publication Critical patent/BRPI9913746B8/pt
Publication of BR9913746F8 publication Critical patent/BR9913746F8/pt
Publication of BRPI9913746F8 publication Critical patent/BRPI9913746F8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C07D213/77—Hydrazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/86—Hydrazides; Thio or imino analogues thereof
    • C07D213/87—Hydrazides; Thio or imino analogues thereof in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"derivado de piridínio, processo para a preparação do mesmo, uso do mesmo, composição farmacêutica, processo para preparação de uma formulação parenteral, e, métodos de tratamento de um paciente diabético e de prevenção ou de tratamento de doenças causadas por diabetes e por complicações relacionadas com o envelhecimento". a invenção descreve novos compostos da série de piridínio úteis para o tratamento da diabetes e de complicações vasculares relacionadas com o envelhecimento, incluindo doença renal, doença nervosa, aterosclerose, retinopatia, distúrbios dermatológicos e descoloração dos dentes, pela ruptura de age pré-formado, ou seus sais farmaceuticamente aceitáveis. a invenção também descreve o processo para a preparação de novos compostos da série e de composição farmacêutica compreendendo um ou mais destes compostos. a invenção descreve adicionalmente um processo de tratamento de um paciente diabético pela administração de compostos quer individualmente quer em combinação com drogas para terapia diabética.
BRC19913746A 1999-10-06 1999-10-15 Derivado de piridínio, processo para a preparação do mesmo, uso do mesmo, composição farmacêutica, processo para preparação de uma formulação parenteral BRPI9913746F8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN828CA1999 1999-10-06
PCT/IB1999/001683 WO2001025208A1 (en) 1999-10-06 1999-10-15 Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof

Publications (8)

Publication Number Publication Date
BR9913746A BR9913746A (pt) 2002-04-23
BR9913746C1 BR9913746C1 (pt) 2002-08-13
BR9913746B1 BR9913746B1 (pt) 2013-03-19
BR9913746E8 true BR9913746E8 (pt) 2018-05-02
BR9913746F1 BR9913746F1 (pt) 2020-07-07
BRPI9913746B8 BRPI9913746B8 (pt) 2021-05-25
BR9913746F8 BR9913746F8 (pt) 2021-11-30
BRPI9913746F8 BRPI9913746F8 (pt) 2022-01-18

Family

ID=11084928

Family Applications (1)

Application Number Title Priority Date Filing Date
BRC19913746A BRPI9913746F8 (pt) 1999-10-06 1999-10-15 Derivado de piridínio, processo para a preparação do mesmo, uso do mesmo, composição farmacêutica, processo para preparação de uma formulação parenteral

Country Status (19)

Country Link
US (2) US6462057B1 (pt)
EP (1) EP1222171B1 (pt)
JP (1) JP4068843B2 (pt)
CN (1) CN100355731C (pt)
AT (1) ATE260256T1 (pt)
AU (1) AU769940B2 (pt)
BR (1) BRPI9913746F8 (pt)
CA (1) CA2344144C (pt)
CZ (1) CZ291789B6 (pt)
DE (1) DE69915143T2 (pt)
DK (1) DK1222171T3 (pt)
ES (1) ES2216644T3 (pt)
HK (1) HK1044335B (pt)
HU (1) HU227523B1 (pt)
MX (1) MXPA02003495A (pt)
PL (1) PL211112B1 (pt)
PT (1) PT1222171E (pt)
RU (1) RU2215000C2 (pt)
WO (1) WO2001025208A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1222171B1 (en) * 1999-10-06 2004-02-25 Torrent Pharmaceuticals Ltd Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
US20020103228A1 (en) * 1999-10-06 2002-08-01 Torrent Pharmaceuticals Ltd. Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications
CA2433425A1 (en) * 2000-12-29 2002-09-06 Alteon, Inc. Method for treating fibrotic diseases or other indications iiic
CZ303214B6 (cs) * 2001-03-21 2012-05-30 Torrent Pharmaceuticals Ltd Pyridiniová sloucenina, zpusob její výroby, její použití, farmaceutický prostredek ji obsahující, zpusob jeho výroby a jeho použití
DK1243581T3 (da) * 2001-03-21 2005-10-31 Torrent Pharmaceuticals Ltd Pyridiniumforbindelser til behandling af AGE-relaterede sygdomme
HUP0400823A3 (en) * 2001-04-05 2010-06-28 Torrent Pharmaceuticals Ltd Heterocyclic compounds for treating aging-related and diabetic vascular complications, their preparation and pharmaceutical compositions containing them
US20050043408A1 (en) * 2001-10-15 2005-02-24 Faustinus Yeboah Anti-glycation agents for preventing age- diabetes- and smoking-related complications
CZ20014034A3 (cs) * 2001-10-19 2003-06-18 Torrent Pharmaceuticals Ltd. Kosmetický prostředek, způsob a prostředek a vychytávání volných radikálů z těla buněk
EP1742630A4 (en) * 2004-04-16 2010-01-20 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND PROKINETIC AGENT
WO2006002983A1 (en) * 2004-07-06 2006-01-12 Novartis Ag Combination of organic compounds
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
MX2009004475A (es) 2006-10-27 2009-08-12 Univ Missouri Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
EP2254563A2 (en) * 2008-01-25 2010-12-01 Torrent Pharmaceuticals Ltd. Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc
US20120058105A1 (en) 2008-06-27 2012-03-08 Martin Kean Chong Ng Method of treatment of vascular complications
KR20120018185A (ko) 2009-05-07 2012-02-29 토렌트 파마슈티칼스 리미티드 당뇨병 치료에 유용한 피페리딘 유도체
AR104274A1 (es) * 2015-04-08 2017-07-12 Torrent Pharmaceuticals Ltd Compuestos piridinio como inhibidores de pag
CA2997463A1 (en) 2015-04-08 2016-10-13 Torrent Pharmaceuticals Limited Pharmaceutical formulations
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH335521A (de) * 1955-06-02 1959-01-15 Cilag Ag Verfahren zur Herstellung neuer quaternärer Salze
US5272176A (en) 1984-03-19 1993-12-21 The Rockefeller University Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
US4758583A (en) 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging
US5137916A (en) 1985-11-14 1992-08-11 The Rockefeller University Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
JPH05216151A (ja) * 1992-02-06 1993-08-27 Konica Corp ハロゲン化銀写真感光材料
US5656261A (en) 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
EP1327887A3 (en) * 1995-01-18 2008-12-10 Synvista Therapeutics, Inc. Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation end products
EP1222171B1 (en) * 1999-10-06 2004-02-25 Torrent Pharmaceuticals Ltd Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof

Also Published As

Publication number Publication date
CZ20011033A3 (cs) 2001-08-15
US6462057B1 (en) 2002-10-08
BRPI9913746B8 (pt) 2021-05-25
US20030092744A1 (en) 2003-05-15
CA2344144A1 (en) 2001-04-12
HK1044335A1 (en) 2002-10-18
DE69915143D1 (de) 2004-04-01
US6624178B2 (en) 2003-09-23
BRPI9913746F8 (pt) 2022-01-18
MXPA02003495A (es) 2004-04-05
DK1222171T3 (da) 2004-07-05
WO2001025208A1 (en) 2001-04-12
HU227523B1 (en) 2011-07-28
HK1044335B (zh) 2004-09-10
BR9913746F8 (pt) 2021-11-30
DE69915143T2 (de) 2004-10-14
BR9913746F1 (pt) 2020-07-07
HUP0104116A3 (en) 2002-04-29
PT1222171E (pt) 2004-07-30
CZ291789B6 (cs) 2003-05-14
BR9913746B1 (pt) 2013-03-19
ES2216644T3 (es) 2004-10-16
PL211112B1 (pl) 2012-04-30
HUP0104116A2 (hu) 2002-03-28
BR9913746A (pt) 2002-04-23
CN100355731C (zh) 2007-12-19
JP2003511369A (ja) 2003-03-25
CN1318056A (zh) 2001-10-17
BR9913746C1 (pt) 2002-08-13
ATE260256T1 (de) 2004-03-15
CA2344144C (en) 2008-12-02
JP4068843B2 (ja) 2008-03-26
RU2215000C2 (ru) 2003-10-27
PL348327A1 (en) 2002-05-20
EP1222171A1 (en) 2002-07-17
EP1222171B1 (en) 2004-02-25
AU5994299A (en) 2001-05-10
AU769940B2 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
BR9913746E8 (pt) derivado de piridínio, processo para a preparação do composto, uso do composto, composição farmacêutica para o tratamento de complicações diabéticas e doenças relacionadas ao envelhecimento, processo para preparação de uma formulação parenteral,processo para o tratamento de um paciente diabético pela ruptura de um age pré-formado dentro do paciente,e,processo de prevenção ou de tratamento de doenças causadas por diabetes e por complicações relacionadas com o envelhecimento.
JPH0222229A (ja) 神経細胞及び神経繊維の疾患もしくは傷害の治療に用いる組み合わせ調合剤
BR0109336A (pt) Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
BRPI0206432A2 (pt) métodos para administrar dois ou mais agentes terapêuticos ativos e para tratar diabetes melito ou sintomas associados com diabetes melito em um humano e sistema de liberação espaçada de medicamento
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
RU94022479A (ru) Применение антиэстрогенных соединений, а также фармацевтически приемлемых солей и сольватов для уменьшения концентрации глюкозы в крови, фармацевтический препарат
WO2006062748A3 (en) Omega-3 fatty acids and dyslipidemic agent for lipid therapy
BR0013065A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ ou ativação aberrante de leucócitos
BR9807319A (pt) Microgrânulos com liberação controlada, para administração oral, contendo cisplatina, processo de preparação dos mesmos, preparação farmacêutica, e, utilização dos microgrânulos.
US20200093833A1 (en) Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
BR9915962A (pt) Composto da série do piridìnio, processos para a preparação de composto da série do piridìnio e de uma formulação parenteral, uso de um composto, composição farmacêutica para tratar complicações diabéticas e doenças associadas ao envelhecimento, e, método para tratar um paciente diabético e para prevenir ou tratar doenças causadas por complicações associadas à diabetes e ao envelhecimento
PT1243581E (pt) Compostos de piridinio uteis no tratamento de doencas relacionadas com age
KR940013503A (ko) 동맥경화증의 예방 또는 치료용 약제학적 조성물
EP0402208B1 (fr) Association de vitamine A à dose physiologique et de différents principes actifs ayant une activité thérapeutique
BR0011714A (pt) Medicamento oftalmológico neuro-protetor e retino-protetor e utilização de um princìpio ativo de medicamento
KR930702985A (ko) 식도암의 치료
RU2267335C1 (ru) Способ комбинированной анальгезии у пожилых пациентов после операций на тазобедренном суставе и бедре
JP5685362B2 (ja) 有痛性末梢糖尿病性神経障害の予防のためのアセチルｌ−カルニチン
ES2425045T3 (es) Acetil-L-carnitina para la prevención de la neuropatía diabética periférica dolorosa
EP1632235A3 (en) Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders
Trope et al. Systemic absorption of topical and subconjunctival gentamicin.
RU2208402C1 (ru) Способ профилактики тромбоза сосудов пересаженного лоскута
Shapiro The Hypoprothrombinemia-Inducing Activity of Link’s Compound# 63 (Methopyranorin)

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/03/2013, OBSERVADAS AS CONDICOES LEGAIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: REFERENTE A 10A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B03H Publication of an application: rectification [chapter 3.8 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: REFENTE A RPI 1649 DE 13/08/2002.QUANTO AOS ITENS (54 E 71).

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B03H Publication of an application: rectification [chapter 3.8 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B06A Patent application procedure suspended [chapter 6.1 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B09A Decision: intention to grant [chapter 9.1 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/03/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/10/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 15/10/2019

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: REFERENTE A RPI 2583 DE 07/07/2020, QUANTO AO ITEM (54) TITULO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/10/1999, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: PATENTE EXTINTA EM 15/10/2019